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Autism spectrum disorder (ASD) is a  complex heterogeneous neurodevelopmental disorder with a  complex pathogenesis. Many 
studies over the last four decades have recognized altered immune responses among individuals diagnosed with ASD. The purpose 
of this critical and comprehensive review is to examine the hypothesis that immune dysfunction is frequently present in those with 
ASD. It was found that often individuals diagnosed with ASD have alterations in immune cells such as T cells, B cells, monocytes, 
natural killer cells, and dendritic cells. Also, many individuals diagnosed with ASD have alterations in immunoglobulins and increased 
autoantibodies. Finally, a significant portion of individuals diagnosed with ASD have elevated peripheral cytokines and chemokines 
and associated neuroinflammation. In conclusion, immune dysregulation and inflammation are important components in the 
diagnosis and treatment of ASD.
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INTRODUCTION
Autism spectrum disorder (ASD) is considered 
a complex and heterogeneous neurologic disorder, 
showing features of core abnormalities in social 
relationship and communication, repetitive behavior 
and deficits in verbal and non‑verbal interaction, with 
stereotyped behaviors and interests and even visual 
dysfunction (APA 2013, Wu et al. 2015, Bakroon and 
Lakshminarayanan 2016). The pathogenesis of ASD is 
complex and controversial, and both nutritional and 
immune causes have been recently associated with this 
complex pathology (Hsiao 2013, Endreffy et al. 2016, 
Fujiwara et al. 2016, Zerbo et al. 2016). Controversial 
issues arose from attempting to distinguishing between 
children’s and adults ASD, and particularly Asperger 
syndrome with high functioning autism in adults, where 
language delays may be used to distinguish the two 
pathologies, as the poor performance on language tests 
also challenges the assumption that early language 
development in Asperger syndrome is essentially normal 
(Howlin 2003, Baron‑Cohem and Wheelwright 2004). 
Immune system and neuroinflammation appear to play 
a fundamental role in ASD development, despite some 
concern about whether it causes ASD onset or regulates 
ASD pathogenesis and symptomatology. Immunity 
plays a pivotal role in the neurodevelopment of central 
and peripheral nervous systems, regulating neuronal 
proliferation, synapse formation, and plasticity, along 
with removing apoptotic neurons, but also actively 
participating in many neurological activities (De Jong et 
al. 2011, Wang et al. 2014, Jašarević et al. 2015, Young et 
al. 2016). Several studies over the last four decades have 
recognized altered immune responses in individuals 
diagnosed with ASD (Hsiao 2013, Noriega and Savelkoul 
2014, Estes and McAllister 2015). Many people with ASD 
frequently display infections, environmental and food 
allergies, asthma, seizures, unexplained skin rashes, and 
persistent intestinal yeast infections (Sakamoto et al. 
2015, Li and Zhou 2016). Also, signs of immune tolerance 
loss, e.g., allergies, over‑reaction to vaccines/infections 
and undiagnosed autoimmune disorders appeared to 
be more commonly present in individuals diagnosed 
with ASD (Kern et al. 2014, Ruggeri et al. 2014, Wang et 
al. 2014). The involvement of the immune system in the 
neurobiological pattern of ASD currently is a topic of 
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intensive research. The purpose of the present review 
is to explore the state‑of‑art research in this field and 
explore the hypothesis that ASD individuals frequently 
also have a significant immune dysfunction.
Alterations in immune cells in ASD
T cells
Potential immune cells involved in ASD, in different 
model species, are listed and detailed in Table I. Recent 
studies reported that children with ASD may have several 
different immune phenotypes and sub‑phenotypes that 
correlate with increasingly severe behavioral impairments 
(Careaga et al. 2015). The causative relationship between 
ASD and immune function impairment has yet far to be 
fully elucidated. T cells play a significant role in adaptive 
immunity, particularly because of their distinctive feature 
dealing with immunological T‑cell memory. Anomalies 
in T cell function were reported in ASD (Jyonouchi et 
al. 2005, Ashwood et al. 2011b, Bailey et al. 2012, Onore 
et al. 2012, Mead and Ashwood 2015) but no causative 
issues were further outlined. Previous reports identified 
a reduced percentage of CD4+ T‑helper cells, lower 
number of T cells (CD2+ cells) and lower percentages and 
number of total lymphocytes in ASD subjects compared 
to controls (Warren et al. 1990, Yonk et al. 1990, Ashwood 
et al. 2011b, Lopez‑Cacho et al. 2016). Furthermore, the 
CD4+ T‑cell subpopulations showed a decrease in CD4RA+ 
T cells, which are responsible for inducing suppressor 
T cells (Yonk et al. 1990, Ahmad et al. 2016). In a recent 
twin‑model with ASD, CD4+ depression was assessed by 
a dysregulation in the production of interferon‑gamma 
(IFN‑γ) and interleukin‑17 (IL‑17), associated with other 
neurological comorbidities (Magid‑Bernstein et al. 2015). 
A decrease in CD4+ T‑cell appears to be a common finding 
in ASD. Several studies in the past reported abnormalities 
in T‑lymphocytes in about 35% of ASD patients with 
decreased numbers of CD4+ T‑cells and T‑helper cells 
(CD4+CD8), altered the CD4/CD8 ratios, and an increased 
number of suppressor T‑cells (CD4+CD8+) (Gupta et al. 1996, 
1998). In support of this, a double‑blind study reported 
a significant reduction of autistic symptoms in 56% of 
Table I. Overview of the studies to date detailing a relationship between ASD and immune function
IMMUNE CELLS
TYPE/SUBTYPE
EXPERIMENTAL 
SETTING  EVIDENCE REFERENCES
T-cell
Th17
Mouse model ↑
Targeting Th17 allows pregnant mothers  
to be protected from viral infections  
causing ASD in offspring
Choi et al. 2016
Cell from subjects ↑ Production of IL-17 in cells from  children with ASD Akintunde et al. 2015
CD4+ Blood-ASD ↓ Depression of peripheral CD4+Dysregulation Th1/Th2/Th17
Yonk et al. 1990,  
Ahmad et al. 2016
CD8+ Blood-ASD ↓
Altered peripheral levels of CD20+ B-cells, 
T(CD8+), CD4+CDw29+, CD2+,  
CD4+CD45RA+ T cells
Yonk et al. 1990
Colonic C8 cells  
and gut γδT-cells Gut specimen
↑ Increase in cell infiltration-Altered gut 
immunity Furlano et al. 2001
CD4+CD25high 
regulatory T cells Children with ASD
↓ Decreased blood levels Mostafa et al. 2010
B-cell
Response to  
estrogens and 
DHT
ASD subjects
↓
↑
Decreased response to hormones,  
with less growth depression and less 
mitochondrial upregulation
Mitochondrial defects
Sharpe et al. 2013a, 2013b
Granulocytes Neutrophils Newborns
↑ Chemokine MCP-1
Zerbo et al. 2014
↓ Chemokines RANTES, MIP-1α
Natural killer 
cells (NK)
CD57+CD3- Children with ASD ↓ Decreased levels in peripheral blood samples Siniscalco et al. 2016
NK, NKT 59 adult patients with ASD
↑ CD25 expression López-Cacho et al. 2016
Monocytes Monocytes,  neopterin 31 ASD children
↑ Increased blood levels Sweeten et al. 2003
Innate cells
Innate immunity ASD children ↓↑ Dysregulated innate immunity Jyonouchi et al. 2005
Cytokine levels ASD subjects ↓↑ Dysregulated cytokines  (TNF-α, IL-8, IL-9, IL-13, IL-15) Pecorelli et al. 2016
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ASD children, following treatment with the potent opiate 
antagonist naltrexone. The drug increased the number of 
T‑helper inducers and reduced the number of T‑cytotoxic 
suppressors, resulting in a normalization of the CD4/CD8 
ratio (Scifo et al. 1996). Those studies were, however, not 
further continued in the following years, probably because 
of new markers and interests in the immunological 
spectrum of ASD. Recent attempts have also tried to 
develop an animal model of autism‑risk stressing on the 
immune disorder pattern (Hsiao et al. 2012). The offspring 
of mothers in mouse models, which underwent a maternal 
immune activation (MIA), showed altered immune profiles. 
The immunological changes included a deficit in CD4+, 
TCRβ(+) Foxp3(+) CD25(+) T regulatory cells, increased 
CD4‑mediated production of IL6 and IL‑17 and increased 
levels of peripheral Gr‑(1)+ cells with abnormalities in 
the myeloid hematopoietic lineage. When irradiated mice 
were re‑populated with immune cells from MIA mice, they 
were not able to restore the immune phenotype, providing 
evidence supportive of the existence of an individual’s 
peripheral context affecting the long‑time reprogramming 
of immune function. However, behaviorally abnormal 
MIA‑derived offspring, which exhibited stereotyped 
and repetitive attitudes and anxiety‑like behaviors and 
were previously irradiated, when transplanted with 
control or MIA‑derived immune populations, restored 
a normal behavioral and neurological pattern, showing 
a fundamental relationship between ASD and immune 
dysregulation (Hsiao et al. 2012). 
From an immunological point of view, CD4+ 
lymphocyte helper‑cell activities are fundamentally 
divided into T‑helper 1 (Th1) (cell‑mediated immunity), 
and Th2 (humoral immunity) subsets. Th1 is the first‑line 
of defense system primarily against viral, fungi, and 
protozoa, while Th2 helps the B‑cells to produce 
antibodies, although this paradigm has been recently 
updated (Moore et al. 2001, Rossignol 2007, Hirahara et 
al. 2016). Current immunology has deeply revised these 
concepts, by introducing further CD4+ populations, most 
of which with regulatory functions. In this perspective, 
the role of T‑cell response in ASD has come to the spotlight 
because of impairments observed in either Th1, Th2 or 
Th17 phenotype content, immune dysregulation in their 
relationship with innate and acquired immunity and the 
B‑cell repertoire and expression of major cytokines, e.g. 
IL‑1β, TNF‑α, IL‑2, IL‑4, IL‑13, IL‑17 and IL‑10 (Moore et al. 
2001, Molloy et al. 2006, Rossignol 2007, Li et al. 2009, Estes 
and McAllister 2016). Furthermore, a number of abnormal 
immune adaptive responses have been reported in ASD 
patients. Previous studies revealed activation of the Th1 
system with increased production of IL‑12 and interferon 
when compared to controls (Stubbs 1995, Singh 1996), 
and was recently confirmed (Ross et al. 2013). Alterations 
in the level of pro‑inflammatory cytokines such as IL‑12, 
IL‑1, IL‑6, TNF‑α, IL‑23 and the brain‑derived neurotrophic 
factor (BDNF) in ASD was recently reported (Ricci et al. 
2013). ASD children express increased IFNγ and IL‑1 
receptor antagonist (IL‑1ra), resulting in a Th1 skewing 
(Croonenberghs et al. 2002a, Goines et al. 2011). Also, in 
ASD patients, compared to controls, an increase in the 
production of markers of cell‑mediated immunity were 
observed, together with augmented T‑cell production 
of TNFα and decreased IL‑10 production was recently 
reported (Rossignol 2007, Ashwood et al. 2011b). Many 
studies indicated that ASD children had an evident shift in 
the CD4+‑cell population from Th1 cells toward Th2 cells 
(Gupta et al. 1996, 1998, Ashwood et al. 2011b). This shift 
might enhance susceptibility to chronic viral infections 
in ASD (Croonenberghs et al. 2002b). Past reports showed 
that ASD children have an increased production of 
immunoglobulin E (IgE) and IL‑4 producing CD4+ T‑cells, 
and lower levels of IL‑2 producing CD4+ T‑cells compared 
to controls (Gupta et al. 1996, 1998), and this was recently 
confirmed (Rossignol 2007, Theoharides 2013). 
Gut epithelial dysfunction and gut microbiome 
impairment were also reported in ASD, due to disorder 
in the T‑cell mediated immune response (Furlano et al. 
2001, Luna et al. 2016). Moreover, past reports showed 
that about 5% of ASD patients have IgA deficiency, and 
30–40% have low serum IgA levels (Gupta et al. 1996, 
Wasilewska et al. 2012). ASD patients often display an 
enhanced sensitivity to gluten, with increased anti‑gliadin 
antibodies compared to healthy individuals (Lau et al. 
2013). This suggests a disorder in the mucosal immunity 
in ASD (Ashwood et al. 2004). This was even confirmed for 
anti‑transglutaminase autoantibodies (Rosenspire et al. 
2011). In ASD, particularly in children with regressive ASD, 
a shift in the immunoglobulin composition in serum, with 
low‑normal IgA and CD23‑expressing B‑cells, was observed 
(Wasilewska et al. 2012). 
Mucosal immunity should also affect regulatory T cells 
(Kinoshita and Takeda 2014). The activity of Th17 cells 
in mucosal immunity has also been associated with the 
role exerted by vitamin D in this context and in mucosal 
immune tolerance (Chirumbolo 2015). This would suggest 
a role for vitamin D in ASD (Mostafa and Al‑Ayadhi 2012, 
Cannell and Grant 2013, Saad et al. 2015). At least, as 
observed in mouse models, an association of impaired 
Th17 function and ASD was reported (Choi et al. 2016). 
Children with ASD express an increased amount of IL‑17 
and IL‑17a, with co‑morbid asthma (Al‑Ayadhi and Mostafa 
2012, Akintunde et al. 2015). Therefore the role of IL‑17 
in ASD appears to be of significant interest. Finally, an 
autistic “endophenotype” able to produce antibodies 
reactive to brain proteins (Connolly et al. 2006, Cabanlit et 
al. 2007), seems to have a typical immunological pattern, 
characterized by 1) the existence and increase of immune 
cells producing proinflammatory cytokines and IL‑10; 
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2) an increase in CD8+ naïve (CD45RA+/CCR7+) T lymphocytes 
and CD8+ effector memory (CD45RA‑/CCR7‑) cells and also 
3) a decrease in CD4+ terminally differentiated (CD45RA‑/
CCR7+) (Saresella et al. 2009). These data also support 
significant alterations in the adaptive immune responses 
in children diagnosed with ASD. 
B cells
Children diagnosed with ASD in comparison to controls 
were reported to either have an increased absolute 
number of B cells per volume of blood of about 20 to 25% 
(Ashwood et al. 2011a), or had no change (Heuer et al. 
2012). Although when comparing the two studies, patients 
differed in median age and the experimental approaches 
were quite different. A recent survey reported that 
variability in single nucleotide polymorphism (SNPs) in 
the CD157 or bone marrow stromal cell antigen‑1 (BST‑1), 
particularly the CT genotype in rs10001565, is frequently 
associated with subjects suffering from ASD as compared 
to controls, and, thus demonstrates the possibility of 
an impaired B‑cell population in ASD (Yokoyama et al. 
2015). It is intriguing to note that both CD38 and CD157 
modulate the innate and adaptive immune response in 
T and B cells (Malavasi et al. 2006). Probably, in subjects 
with ASD, a mitochondrial dysfunction in B‑cells may 
explain why B lymphocytes in ASD exhibit a differential 
immune response to estrogens, dihydrotestosterone, and 
hormone disrupters, which were associated with ASD 
onset (Sharpe et al. 2013a). B‑cell sensitivity to external 
stimuli has also been reported for thimerosal (Sharpe 
et al. 2013b). Individuals with ASD display a reduced 
number of B‑cells and an increased amount of NK cells 
(Bressler et al. 2012). This evidence may suggest that the 
reduction in immunoglobulin levels observed in ASD may 
be a consequence of B‑cell depletion or impairment, but 
recent findings seem to contradict this opinion (Hauer et 
al. 2012). 
Peripheral monocluate cells
Monocytes differentiate into macrophages upon 
migration into the surrounding tissues. Macrophages, 
in turn, phagocytize pathogens and present antigens to 
lymphocytes (Berdowska and Zwirska‑Korczala 2001, 
Sweeten et al. 2003). When stimulated by IFNγ, monocytes 
and macrophages produce increased amounts of neopterin. 
High levels of neopterin could serve as an indicator of 
monocyte/macrophage activation, as well as activation 
of T cells and cell‑mediated immunity (Berdowska and 
Zwirska‑Korczala 2001, Zhao et al. 2015). Previous studies 
in ASD revealed a somewhat higher number of absolute 
monocyte counts and a significantly higher percentage 
of monocytes, in relation to total leukocytes in ASD as 
compared to healthy controls (Denny et al. 1996, Sweeten 
et al. 2003). Furthermore, augmented expression of 
activation markers on these monocytes suggested that 
these cells were in an activated state (Ashwood et al. 
2011a). A fundamental question that should arise from 
ASD research is the impact of neuroimmune alterations in 
ASD (Gottfried et al. 2015, Siniscalco 2015). Immunological 
impairment in innate immunity was observed in ASD. 
Peripheral blood monocytes were found to increase the 
release inflammatory cytokines such as IL‑1β, TNF‑α, 
and IL‑6 in response to TLR2 and TLR4 stimulus and, 
particularly, IL‑6 and IL‑10 (Jyonouchi et al. 2005, Manzardo 
et al. 2012, Jyonouchi et al. 2014). Increased production of 
IL‑6 and IL‑1β was associated with increased impairment 
of social behaviors in individuals diagnosed with ASD was 
observed (Enstrom et al. 2009). Innate immunity, therefore, 
plays a fundamental role in ASD development. Innate 
immunity‑related cytokines and chemokines are altered in 
ASD compared with controls, and suggest these molecules 
may be used as ASD risk immune markers (Zerbo et al. 
2014, Masi et al. 2015, Xu et al. 2015). Alternative mRNA 
splicing disorder in ASD may explain some impairment in 
monocyte/macrophage and natural killer cells (Stamova et 
al. 2013). 
All these observations suggest that impairment in 
innate immunity may have a role in ASD, but are not 
necessarily causative. The immunological profile of ASD 
subjects regarding innate immunity may be somewhat 
more controversial. Despite a pro‑inflammatory hallmark 
in ASD, recent reports showed that ASD individuals 
in comparison to controls have a cytokine pattern of 
peripheral monocyte/macrophages producing reduced 
pro‑inflammatory cytokines following activation of 
TLR7/8 (IL‑6, IL‑23), TLR2/6 (IL‑6), TLR4 (IL‑12p40), 
without stimuli (IL‑1ß, IL‑6, and TNF‑α) after challenging 
with T cell mitogens (IFN‑γ, IL‑17, and IL‑12p40), and 
with antigens from the genus Candida (IL‑10 or IL‑12p40) 
(Jyonouchi et al. 2012). Recent evidence showed that 
the endocannabinoid receptor, which is involved in 
a system able to modulate the immune response via the 
cannabinoid receptor type 2(CB2R), and while is highly 
expressed in macrophages and microglia, its function 
is impaired in ASD patients (Siniscalco et al. 2014). 
Many soluble factors, besides leukocyte receptors, are 
fundamental markers in ASD. For example, brain IL‑6 
is considered a major neuroimmune mediator in ASD 
onset and development (Wei et al. 2013). Macrophage 
activity is also altered in ASD. As another example, 
several ligands of CCR4, such as macrophage‑derived 
chemokines (MDC) or CCL22 and thymus and activated/
regulated chemokine (TARC) or CCL17, were reported 
to be elevated in ASD children as compared to controls 
(Al Ayadhi and Mostafa 2013). It was recently reported 
for macrophage migration inhibitory factor (MIF) that 
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there was a genetic association between a functional 
polymorphism in the genetic promoter for MIF and 
ASD. As a consequence, it was suggested that MIF may 
play an important functional role in ASD pathogenesis 
(Grigorenko et al. 2008).
Natural killer (NK) cells
Ashwood and others (2011a) reported that the absolute 
numbers of NK cells were approximately 40% higher in 
children diagnosed with ASD compared to controls. These 
data are in agreement with Enstrom and colleagues (2010) 
who reported greater numbers of NK cells and increased 
gene expression of NK cell‑related cellular receptors and 
effector molecules in children diagnosed with ASD in 
comparison to controls (Enstrom et al. 2010). However, 
Vojdani and others (2008) have reported 45% of the ASD 
children had a decreased responsiveness of NK cells to 
in‑vitro stimulation (Vojdani et al. 2008). The increase in 
NK cell numbers may, therefore, reveal a compensatory 
mechanism to increase cell numbers to make up for 
NK cell function deficiencies (Ashwood et al. 2011a). 
The number of CD57+CD3‑lymphocytes appeared to 
fall below the clinically accepted range in ASD children 
(Siniscalco et al. 2016). Moreover, children with ASD have 
activating KIR/HLA complexes (aKIR/HLA), where KIR is 
the killer cell immune globulin‑like receptor, expressed 
on NK cells, i.e., in utero these immune interactions 
may promote immune activation in ASD (Guerini et al. 
2014). Abnormalities in NK cells in ASD may predispose 
individuals to the development of autoimmunity and/
or adverse neuroimmune interactions during critical 
periods of development (Enstrom et al. 2010). The 
presence of autoantibodies towards central nervous 
system (CNS) proteins is a common finding in ASD and 
may reflect an ongoing inflammatory and or autoimmune 
process in individuals with ASD that could be started by 
abnormal NK cell activation (Ashwood et al. 2006). In this 
circumstance, the expansion of NK cell numbers may 
result from intensified immune/autoimmune responses 
probably mediated through the increased production 
of homeostatic and growth factors such as cytokines 
(Ashwood et al. 2011a).
Dendritic cells
Dendritic cells actively participate in innate immunity 
and also modulate the adaptive immune response 
and immune tolerance. They are phagocytic cells, 
expressing several innate pattern‑recognition receptors 
(PPRs), which are targeted by pathogen‑associated 
molecular pattern molecules (PAMPs) on microbes or 
damage‑associated molecular pattern molecules of 
endogenous tissues (Steinman 2007, Breece et al. 2013). 
After binding these ligands/antigens, dendritic cells 
undertake maturation steps that increase mobility for 
migration, produce chemokines to convert other immune 
cells, and co‑stimulatory molecules for priming of naïve 
T cells or stimulation of effector T cells and secrete large 
quantities of cytokines that control neighboring immune 
cells (Banchereau et al. 2000, Ueno et al. 2007, Breece et 
al. 2013). Myeloid dendritic cells frequency is augmented 
in ASD (Breece et al. 2013). Both myeloid dendritic cells, 
with phenotype defined as Lin‑1‑BDCA1+CD11c+ and 
Lin‑1‑BDCA3+CD123‑) and plasmacytoid dendritic cells, 
namely (Lin‑1‑BDCA2+CD123+ or Lin‑1‑BDCA4+CD11c‑) are 
impaired in ASD, where plasmacytoid phenotypes seem to 
be associated with developmental regression in ASD and 
an increase in the amygdala volume (Breece et al. 2013). 
Moreover, dendritic cells play a significant role in inducing 
both central and peripheral tolerance. Dendritic cells 
in the periphery continuously capture and present low 
dose non‑immunogenic antigens to T cells with limited 
or absent co‑stimulation to maintain tolerance either by 
deletion, the induction of unresponsiveness or generation 
of adaptive T regulatory cells (Steinman 2007). Breece and 
others (2013) found that there are increased circulating 
frequencies of blood myeloid dendritic cells in young 
children diagnosed with ASD. These increased frequencies 
were associated with an increased volume of the amygdalas 
and increased repetitive behaviors in patients with ASD 
(Breece et al. 2013).
Alterations in immunoglobulins in ASD
Previous studies have reported changes in the levels 
of immunoglobulins among individuals diagnosed with 
ASD. However, these reports are controversial, and no 
clear consensus has been reached. IgG and IgM are either 
increased (Croonenberghs et al. 2002b) or decreased (Gupta 
et al. 1996, Heuer et al. 2008) in ASD individuals compared 
to healthy controls. The supposed presence in the serum 
of anti‑neuronal antibodies including anti‑glutamic acid 
decarboxylase antibodies (anti‑GAD), has been recently 
dismissed (Bayram et al. 2016). Plasma markers in ASD 
were assessed and revealed serum IgG antibodies to 
casein, egg whites, egg yolks, and peanuts (Esparham et 
al. 2015). Many ASD subjects showed polymorphism in 
the glutathione scavenging system, namely the absence of 
glutathione S‑transferase (GSTM) at the 1p13.3 location, 
and heterozygosity for the glutathione S‑transferase I105V 
(GSTP1), while most of ASD patients exhibited genetic 
polymorphism of the mitochondrial gene superoxide 
dismutase A16V (SOD2) (Esparham et al. 2015). Therefore, 
nutritional, environmental and immunological factors 
should play a significant role in ASD pathogenesis. Heuer 
and others (2008) reported low levels of immunoglobulin 
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(IgG and IgM) in children diagnosed with ASD, which also 
correlated with increased behavioral severity of autistic 
symptoms on the Aberrant Behavior Checklist (ABC) (Heuer 
et al. 2008). However, in comparing the previous studies, 
the differences are attributed to different sample sizes, 
the median age of patients with ASD, variations in types 
of control samples, and different experimental approaches 
(Heuer et al. 2008). Even alterations in maternal immune 
globulins and the presence of autoantibodies may cause 
ASD in the offspring (Poleataev et al. 2014, Brown et al. 
2015). The presence of autoantibodies is also reported 
in ASD children (Elamin and Al‑Ayadhi 2014, Mostafa 
et al. 2014). Further research is needed to enhance our 
comprehension of dysregulated antibodies in ASD.
Peripheral cytokines and chemokines in ASD
Both cytokines and chemokines are small proteins 
secreted by immune or other somatic cells with 
hormone‑like, informative activity. They have the ability 
to induce modifications in neighboring responsive cells. 
Some cytokines are considered pro‑inflammatory and 
can be induced during an immune response to recruit 
cells of the immune system to the site of infection (Wang 
et al. 2014). Individuals diagnosed with ASD have been 
observed to have altered cytokine profiles compared to 
healthy controls, and to be in a chronic state of cytokine 
induction (Ashwood et al. 2011c, 2011d, Wang et al. 2014). 
Patients diagnosed with ASD in comparison to controls 
have a diminished Th2 anti‑inflammatory response and 
an increased Th1 pro‑inflammatory cytokine response. 
This includes an enhanced innate and adaptive immune 
reaction through the Th1 pathway and suggests 
that localized brain inflammation and autoimmune 
dysfunction may be involved in ASD (Ashwood et al. 
2011c, 2011d, Wang et al. 2014). More specifically, 
Ashwood and others (2011c, 2011d) reported elevated 
cytokines including IL‑1β, IL‑6, IL‑8 and IL‑12p40, 
MCP‑1, RANTES and eotaxin in children diagnosed with 
ASD in comparison to controls (Ashwood et al. 2011c, 
2011d). It was recently confirmed that persons with 
ASD in comparison to controls have cytokine functional 
impairment (Goines and Ashwood 2013, Krakowiak 
et al. 2015, Masi et al. 2015, Pecorelli et al. 2016). In 
previous studies, elevated inflammatory mediators were 
associated with more abnormal behaviors in individuals 
with ASD (Ashwood et al. 2011c, 2011d). It was also 
reported in other studies that increased levels of 
inflammatory cytokines in plasma of children diagnosed 
with ASD in comparison to controls were observed 
for IFNγ (Singh 1996), MIF (Grigorenko et al. 2008), 
platelet‑derived growth factor‑BB (PDGF‑BB) (Kajizuka 
et al. 2010), and dysregulation of IL‑18 (Businaro et al. 
2016). The immune dysregulation of cells should also 
affect the function and production of cytokines.
Autoantibodies
Autoantibodies were reported to numerous and varied 
targets in ASD. They may point to cellular damage involved 
in increasing inflammation, revealing antigens otherwise 
hidden and/or epitope spreading (Onore et al. 2012). 
Elevated serum autoantibodies to many neuron‑specific 
antigens and cross‑reactive peptides have been found in ASD 
children including antibodies directed against cerebellar 
Purkinje cells and other neural proteins (Onore et al. 2012, 
Wang et al. 2014), but some of the findings have been 
inconsistent between studies. Multiple studies reported an 
elevated number of autoantibodies that react against the 
brain and central nervous system in children diagnosed 
with ASD when compared to healthy controls (Cabanlit et 
al. 2007, Wills et al. 2007). It was not only brain‑specific IgGs 
autoantibodies occurred at a high frequency among children 
diagnosed with ASD in comparison to controls (Cabanlit et 
al. 2007, Elamin and Al‑Ayadhi 2014), but also anti‑neuron 
antibodies that were associated with more severe cognitive 
and behavioral profiles in children diagnosed with ASD 
(Piras et al. 2014). Interestingly, brain autoantibodies are 
also associated with lower serum docosahexaenoic acids 
(DHA) levels in ASD in comparison to controls (Mostafa et 
al. 2015) and higher blood mercury (BHg) levels (Mostafa 
and Refai 2007, Mostafa and Al‑Ayadhi 2015, Mostafa et al. 
2016a). High Hg levels in children with ASD may relate to 
increased exposure to Hg, but can also be a consequence 
of a decreased ability to excrete Hg, leading to a higher 
body‑burden (Khaled et al. 2016). Neuroinflammation, with 
increased levels of neurokinin A, is seen in some children 
with ASD and is evidenced by elevated BHg levels. In fact, 
a recent study found a positive relationship between 
the Childhood Autism Rating Scale (CARS) scores and 
the levels of serum neurokinin A and BHg (Mostafa et al. 
2016a). Furthermore, Pb induces neuroinflammation and 
autoimmunity in ASD (Mostafa et al. 2016b). A recent study 
suggests that increased levels of BPb in some children with 
ASD may trigger the production of serum anti‑ribosomal 
P antibodies (Mostafa et al. 2016b). It has been reported 
that ASD children often have a lower zinc (Zn)‑to‑copper 
(Cu) ratio in blood compared to healthy controls (Faber 
et al. 2009, Li et al. 2014, Crăciun et al. 2016) and children 
with other neurological disorders (Macedoni‑Lukšič et al. 
2015). It has been suggested that metallothionein (MT) 
dysfunction may occur as a cause of Hg accumulation in 
children with ASD, and the same dysfunction may also 
lead to Zn deficiency (Bjørklund 2013). Zinc plays a major 
role in the immune system, and Zn deficient subjects 
may experience increased susceptibility to a variety of 
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pathogens. Both trace elements (or heavy metals) and 
autoantibodies may be causes of neuroinflammation. 
Many researchers suggested the presence of maternal 
autoantibodies that can have a detrimental effect on 
fetal brain development during pregnancy. Maternal 
pathogenic autoantibodies can reach the fetus, affecting 
the fetal brain tissue (Zimmerman et al. 2007, Croen et al. 
2008). Therefore, it is possible that brain‑specific maternal 
autoantibodies might have an impact in some neurological 
developmental disorders. Also, children diagnosed with 
ASD in comparison to controls more frequently have 
a family history of autoimmune disorders, such as type 
1 diabetes and ulcerative colitis (Zimmerman et al. 2007, 
Croen et al. 2008, Wang et al. 2014).
Neuroinflammation and neurobiology in ASD
What are the implications of the immune dysregulated 
function observed in ASD? Is immune dysregulated 
function a primary cause or rather an ancillary source of 
the etiopathogenesis of ASD? 
ASD is one of an increasing number of neurological 
disorders in both children and adults that are found to 
involve a neuroinflammatory process, which can occur 
in the absence of overt leukocyte infiltration. One of the 
main indicators of neuroinflammation in ASD is microglial 
activation. Microglia are the primary immune cells of 
the CNS and are very similar to peripheral macrophages. 
Furthermore, it is reported that microglia defend the 
brain by clearing cellular debris and dead neurons from 
the nervous tissue through phagocytosis. However, when 
microglial activation is exaggerated and sustained, this 
can lead to collateral damage or damage of healthy tissue 
(Rodriguez and Kern 2011). For example, excessive and 
sustained microglial activation can result in the loss of 
healthy synaptic connections. Exaggerated and sustained 
microglial activation is consistently found in ASD (Vargas 
et al. 2005). Inflammation in postmortem brain specimens 
of individuals diagnosed with ASD has been observed, 
specifically, in the cerebellum, anterior cingular gyrus and 
the mid‑frontal regions of the brain (Vargas et al. 2005). 
Neuroglial activation and presence of increased levels of 
inflammatory cytokines such as IFN‑γ, IL‑1β, IL‑6, TNF‑α 
and chemokines CCL‑2 were found in the brain tissue of 
individuals diagnosed with ASD. Also, accumulation of 
macrophages chemoattractant protein‑1 (MCP‑1) and 
inflammatory cells (microglia and astroglia) around the 
blood vessels were reported, and suggest an inflammation 
of the blood vessels. Also, an increased pro‑inflammatory 
cytokine profile in the cerebral spinal fluid (CSF) was 
reported in living ASD children (Vargas et al. 2005, Morgan 
et al. 2010). The cerebellum, in particular, showed the 
most prominent histological changes and microglial 
activation in ASD. This emphasizes the role of microglia 
in the neuroinflammation pattern of ASD. Moreover, 
some of the cerebellar tissues had an accumulation of 
perivascular macrophages and monocytes and deposition 
of complement membrane attack complexes (Vargas et 
al. 2005). Activation of microglial cells and perivascular 
macrophages was measured by increased MHC II expression 
and were observed in the cortical regions, white matter, and 
cerebellum of patients diagnosed with ASD in comparison 
to controls. This microglial and astroglial activation in the 
cerebellum was associated with degenerating Purkinje 
cells, granule cells, and axons (Vargas et al. 2005). Altered 
microglial profiles found in post‑mortem brain samples 
from ASD patients in comparison to controls showed an 
increase in average microglial somal volume in white 
matter and an increase in microglial density in gray matter 
(Morgan et al. 2010). Also, postmortem temporal cortex 
samples from ASD and general population controls were 
assessed for transcriptome differences and it was observed 
that samples from ASD individuals showed increases in 
expression of immune‑related genes (Garbett et al. 2008). 
It was also previously revealed that individuals diagnosed 
with ASD in comparison to controls have an inflammatory 
response presenting as an increased lymphocytes and 
proinflammatory cytokines, including TNF‑α and IFN‑γ 
and less of the anti‑inflammatory cytokine IL‑10 (Torrente 
et al. 2002, Ashwood et al. 2004, Nakagawa and Chiba 
2016). As a result, among individuals diagnosed with ASD, 
inflammation can become chronic.
Recent findings suggested that imbalances in the 
neuro‑immune function in ASD are signaling an ongoing 
neuroinflammation process. Some researchers have 
suggested a possible allergic response from the brain as 
a cause of ASD (Theoharides 2013, Theoharides et al. 2016), 
where mast cell activation is involved (Theoharides et al. 
2012) and possibly neurotensin and other stress‑related 
hormones, such as corticotrophin releasing hormone (CRH), 
play a significant role (Tsilioni et al. 2014). Besides the 
neuroinflammatory perspective, ASD has been associated 
with deep functional disorders in neuronal function. 
For example, altered neural connectivity in inhibitory 
and excitatory cortical circuits based fundamentally 
on functional non‑invasive studies showing atypical 
synchronization and connectivity patterns between 
cortical areas was revealed in children and adults with ASD 
in comparison to controls (Zikopoulos and Barbas 2013). 
Furthermore, investigators have suggested that changes in 
prefrontal axons and their network disruption may cause 
ASD (Zikopoulos and Barbas 2010). It is rather difficult, 
at present, to know how immunophenotype differences, 
altered immune function, and immune dysregulation may 
interact or contribute to other potential pathomechanisms 
of ASD such as atypical interneuron connectivity or mirror 
neuron defects, which could be related to autoimmune 
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processes or immune imbalances in the brain. It is 
tempting to speculate that astrocyte function may be the 
bottleneck of a possible suggestive answer to this question 
(Bianco‑Suarez et al. 2016). The neurobiological pattern of 
ASD has recently introduced the role of mirror neurons 
(Schulte‑Rüther et al. 2016, Linkovski et al. 2016, Saffin and 
Tohid 2016). Mirror neurons exert direct action that impact 
the occipital cortex, cingulate cortex, insula and dorsal 
prefrontal cortex in ASD (Yang and Hoffmann 2015). Future 
research should elucidate if these disorders may come 
either from neuroinflammation events or dysregulation in 
the astrocyte‑synapse interaction. 
CONCLUSIONS
ASD is a complex heterogeneous neurodevelopmental 
disorder. Immune dysregulation and inflammation 
are important components of ASD and are significant 
to diagnosis and treatment of the disorder. Many 
animal models can provide insights into the role of 
neuroinflammation in ASD onset and pathogenesis 
(Zatkova et al. 2016, Codagnone et al. 2015) and certainly 
the use of a mouse model system such as the mGluR5 
knockout support the role of neuroinflammation in 
cognitive disorders related to ASD (Zantomio et al. 2015). 
The dysfunctional immunophenotype seen in subjects 
with ASD may play a pivotal role in ASD pathogenesis and, 
thus, may be a therapeutic target of future interest. It is 
possible that understanding the role of mirror neurons 
in the dorsal prefrontal cortex may be important to 
neurodevelopment, but it is also possible that there is an 
important role for astrocytes in neurodevelopment. It was 
recently revealed that dysregulation of some micro‑RNAs, 
for example, miR‑146a, miR‑221, and miR‑656, in skin 
fibroblasts are associated with the onset of ASD (Nguyen et 
al. 2016). This evidence might indirectly support the role 
of reconstitution of damaged tissue in the pathogenesis 
of ADS, as occurs in epilepsy (Kim et al. 2016). Glia could 
also exert a significant role in ASD, an immune injury or 
a chemical insults. Future research should improve our 
knowledge about the role, if causative or consequential, 
of the immune impairment observed in ASD, which could 
potentially allow for targeted therapeutics. However, 
to date, it has not been elucidated whether immune 
disorders are causative of ASD or if ASD causes immune 
dysfunction. Genetic polymorphism exists, which, could 
drive immune tolerance or exacerbate immune responses 
towards the development of ASD. The aberrations of 
cytokine immune response, neuroinflammation in the CSF 
and brain tissue, and peripheral immune abnormalities in 
both the innate and adaptive responses among persons 
with ASD suggest that they could be causative of the 
disorder or a comorbidity of the disorder. The use of 
the described immune abnormalities in this review as 
biomarkers should further help in the early identification 
and treatment of ASD. Biomarkers or miRNAs will also 
be important to further understand the potentials links 
between immune dysregulation and resulting changes in 
neural connectivity and behavior. More research is needed 
to explain the mechanisms of immune dysfunction and 
neuroinflammation in ASD, and how these aberrations 
affect the neurological and behavioral changes in ASD.
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